EMPA, a sodium glucose cotransporter 2 inhibitor (SGLT2i), is a new oral hypoglycemic agent for the treatment of type 2 diabetes mellitus (T2DM). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.